(function(){var src_url="https://spshared.5min.com/Scripts/PlayerSeed.js?playList=519279091%2C519217671%2C519276415&height=&width=100&sid=577&origin=SOLR&responsive=true&ratio=wide&align=center&relatedMode=2&relatedBottomHeight=60&companionPos=&hasCompanion=false&autoStart=false&colorPallet=%23FFEB00&videoControlDisplayColor=%23191919&shuffle=0&isAP=1&pgType=cmsPlugin&pgTypeId=addToPost-top&onVideoDataLoaded=track5min.DL&onTimeUpdate=track5min.TC&onVideoDataLoaded=HPTrack.Vid.DL&onTimeUpdate=HPTrack.Vid.TC";if (typeof(commercial_video) == "object") {src_url += "&siteSection="+commercial_video.site_and_category;if (commercial_video.package) {src_url += "&sponsorship="+commercial_video.package;}}var script = document.createElement("script");script.src = src_url;script.async = true;var placeholder = document.querySelector(".js-fivemin-script");placeholder.parentElement.replaceChild(script, placeholder);})(); Looks like Turing's test was a failure. Turing Pharmaceuticals is reneging on its promise to cut the cost of the lifesaving drug Daraprim, after buying the rights to the drug in August and raising the price fiftyfold to $750 per per pill from $13.50.